donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ADAP Adaptimmune Therapeutics

2.399
+0.149+6.64%
Trading Session 08/12 15:10 ET
High
2.540
Open
2.270
Turnover
1.28M
Low
2.270
Pre Close
2.250
Volume
520.17K
Market Cap
391.97M
P/E(TTM)
Loss
52wk High
6.860
Shares
163.37M
P/E(Static)
Loss
52wk Low
1.260
Float Cap
207.08M
Bid/Ask %
0.00%
Historical High
21.570
Shs Float
86.31M
Volume Ratio
2.19
Historical Low
0.709
Dividend TTM
--
Div Yield TTM
--
P/B
2.76
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.60%
Amplitude
12.00%
Avg Price
2.468
Lot Size
1
Float Cap
207.08M
Bid/Ask %
0.00%
Historical High
21.570
Shs Float
86.31M
Volume Ratio
2.19
Historical Low
0.709
Dividend TTM
--
P/B
2.76
Dividend LFY
--
Turnover Ratio
0.60%
Amplitude
12.00%
Avg Price
2.468
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company’s specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing αβ T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
CEO: Rawcliffe, Adrian G.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...